ESMO Open (Oct 2020)

Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan

  • Simone Mathoulin-Pélissier,
  • Antoine Italiano,
  • Anne Boland,
  • Jean-François Deleuze,
  • Helene Blons,
  • Pierre Laurent-Puig,
  • Carine Bellera,
  • Céline Auzanneau,
  • Delphine Bacq,
  • Marlène Boucheix,
  • Aurélien Bourdon,
  • Emmanuelle Chollet,
  • Christine Chomienne,
  • Christelle Delmas,
  • Derek Dinart,
  • Hélène Espérou,
  • Flore Geillon,
  • Damien Geneste,
  • Delphine Jean,
  • Emmanuel Khalifa,
  • Yec'han Laizet,
  • Franck Lethimonnier,
  • Claire Lévy-Marchal,
  • Carlo Lucchesi,
  • Carine Malle,
  • Pierre Mancini,
  • Vincent Meyer,
  • Palomares Marie-Ange,
  • Géraldine Perkins,
  • Sabrina Sellan-Albert,
  • Isabelle Soubeyran,
  • Cédric Wallet

DOI
https://doi.org/10.1136/esmoopen-2020-000744
Journal volume & issue
Vol. 5, no. 4

Abstract

Read online

Background Whole exome sequencing and RNA sequencing (WES/RNASeq) should now be implemented in the clinical practice in order to increase access to optimal care for cancer patients. Providing results to Tumour Boards in a relevant time frame—that is, compatible with the clinical pathway—is crucial. Assessing the feasibility of this implementation in the French care system is the primary objective of the Multipli study, as one of the four pilot projects of the national France Genomic Medicine 2025 (FGM 2025) plan. The Multipli study encompasses two innovative trials which will be driven in around 2400 patients suffering from a soft-tissue sarcoma (Multisarc) or a metastatic colorectal carcinoma (Acompli).Methods Prior to launching the FGM 2025 cancer pilot study itself, the performance of the Multipli genomic workflow has been evaluated through each step, from the samples collection to the Molecular Tumour Board (MTB) report. Two Multipli-assigned INCa-labelled molecular genetics centres, the CEA-CNRGH sequencing platform and the Institut Bergonié’s Bioinformatics Platform were involved in a multicentric study. The duration of each step of the genomic workflow was monitored and bottlenecks were identified.Results Thirty barriers which could affect the quality of the samples, sequencing results and the duration of each step of the genomic pathway were identified and mastered. The global turnaround time from the sample reception to the MTB report was of 44 calendar days.Conclusion Our results demonstrate the feasibility of tumour genomic analysis by WES/RNASeq within a time frame compatible with the current cancer patient care. Lessons learnt from the Multipli WES/RNASeq Platforms Workflow Study will constitute guidelines for the forthcoming Multipli study and more broadly for the future clinical routine practice in the first two France Genomic Medicine 2025 platforms.